Various pathways, such as the Wnt/β-catenin, NF-κB, EGFR, STAT3, and Nrf2-ARE pathways, mediate the initiation, progression, and migration of CRC and are thus ideal sites for targeted therapy. The gene discussed is NFKB1; the disease is colorectal carcinoma.